Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Metastatic progression is associated with dynamic changes in the local microenvironment.

Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ.

Nat Commun. 2016 Sep 15;7:12819. doi: 10.1038/ncomms12819.

2.

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.

Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Löhr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A.

Gut. 2018 Mar;67(3):497-507. doi: 10.1136/gutjnl-2016-311954. Epub 2017 Jan 10.

3.

Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.

Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M.

Cancer Treat Rev. 2014 Feb;40(1):118-28. doi: 10.1016/j.ctrv.2013.04.004. Epub 2013 Jul 9. Review.

PMID:
23849556
4.

Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.

Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D'Andrea MR.

World J Gastroenterol. 2017 Aug 28;23(32):5875-5886. doi: 10.3748/wjg.v23.i32.5875. Review.

5.

Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.

Gastroenterology. 2015 Dec;149(7):1932-1943.e9. doi: 10.1053/j.gastro.2015.07.058. Epub 2015 Aug 7.

6.

Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.

Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L.

Tumour Biol. 2016 Nov;37(11):15283-15291. Epub 2016 Sep 30.

PMID:
27696296
7.

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.

De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M.

BMC Cancer. 2016 Sep 2;16(1):709. doi: 10.1186/s12885-016-2671-9.

8.

Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.

Grünwald B, Harant V, Schaten S, Frühschütz M, Spallek R, Höchst B, Stutzer K, Berchtold S, Erkan M, Prokopchuk O, Martignoni M, Esposito I, Heikenwalder M, Gupta A, Siveke J, Saftig P, Knolle P, Wohlleber D, Krüger A.

Gastroenterology. 2016 Nov;151(5):1011-1024.e7. doi: 10.1053/j.gastro.2016.07.043. Epub 2016 Aug 6.

PMID:
27506299
9.

Hypervascular liver metastasis from hypovascular ductal cell carcinoma of the pancreas.

Noda A, Inaba K, Sakuragi S, Moriguchi T, Tanahashi T, Komaki T, Kimura H, Hirakawa K, Teramae N, Fukui S, Nishimoto Y, Kagawa K.

Intern Med. 2001 Mar;40(3):227-31.

10.

A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.

Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ER.

Biomaterials. 2016 Jul;93:71-82. doi: 10.1016/j.biomaterials.2016.03.044. Epub 2016 Mar 31.

11.

Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.

Dadi N, Stanley M, Shahda S, O'Neil BH, Sehdev A.

Anticancer Res. 2017 Oct;37(10):5533-5539. Review.

12.

Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.

Zhao X, Fan W, Xu Z, Chen H, He Y, Yang G, Yang G, Hu H, Tang S, Wang P, Zhang Z, Xu P, Yu M.

Oncotarget. 2016 Dec 6;7(49):81110-81122. doi: 10.18632/oncotarget.13212.

13.

Gemcitabine resistance in pancreatic ductal adenocarcinoma.

Binenbaum Y, Na'ara S, Gil Z.

Drug Resist Updat. 2015 Nov;23:55-68. doi: 10.1016/j.drup.2015.10.002. Epub 2015 Nov 3. Review.

PMID:
26690340
14.

Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.

Cui L, Nakano K, Obchoei S, Setoguchi K, Matsumoto M, Yamamoto T, Obika S, Shimada K, Hiraoka N.

Gastroenterology. 2017 Jul;153(1):292-306.e2. doi: 10.1053/j.gastro.2017.03.050. Epub 2017 Apr 5.

PMID:
28390868
15.

Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?

Frigerio I, Regi P, Giardino A, Scopelliti F, Girelli R, Bassi C, Gobbo S, Martini PT, Capelli P, D'Onofrio M, Malleo G, Maggino L, Viviani E, Butturini G.

Ann Surg Oncol. 2017 Aug;24(8):2397-2403. doi: 10.1245/s10434-017-5885-4. Epub 2017 May 17.

PMID:
28516291
16.

The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma.

Wang LM, Silva MA, D'Costa Z, Bockelmann R, Soonawalla Z, Liu S, O'Neill E, Mukherjee S, McKenna WG, Muschel R, Fokas E.

Oncotarget. 2016 Jan 26;7(4):4183-94. doi: 10.18632/oncotarget.6770.

17.

Therapeutic effects of Argyrin F in pancreatic adenocarcinoma.

Chen X, Bui KC, Barat S, Thi Nguyen ML, Bozko P, Sipos B, Kalesse M, Malek NP, Plentz RR.

Cancer Lett. 2017 Jul 28;399:20-28. doi: 10.1016/j.canlet.2017.04.003. Epub 2017 Apr 10.

PMID:
28408354
18.

Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.

Qian W, Li J, Chen K, Jiang Z, Cheng L, Zhou C, Yan B, Cao J, Ma Q, Duan W.

Life Sci. 2018 Sep 1;208:253-261. doi: 10.1016/j.lfs.2018.07.046. Epub 2018 Jul 25.

PMID:
30053447
19.

Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle.

Ernsting MJ, Hoang B, Lohse I, Undzys E, Cao P, Do T, Gill B, Pintilie M, Hedley D, Li SD.

J Control Release. 2015 May 28;206:122-30. doi: 10.1016/j.jconrel.2015.03.023. Epub 2015 Mar 21.

20.

KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.

Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E.

Oncology. 2011;81(1):3-8. doi: 10.1159/000330194. Epub 2011 Sep 2.

PMID:
21894049

Supplemental Content

Support Center